Mitochondrial Reactive Oxygen Species Are Essential for the Development of Psoriatic Inflammation.
Animals
Biomarkers
Cytokines
/ metabolism
Disease Models, Animal
Disease Susceptibility
Immunophenotyping
Inflammation Mediators
/ metabolism
Membrane Potential, Mitochondrial
Metabolome
Metabolomics
/ methods
Mice
Mice, Knockout
Mitochondria
/ genetics
Psoriasis
/ diagnosis
Reactive Oxygen Species
/ metabolism
C1qbp/p32
IL-1β
dendritic cells
mitochondrial ROS
psoriasis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
26
05
2021
accepted:
16
07
2021
entrez:
23
8
2021
pubmed:
24
8
2021
medline:
24
12
2021
Statut:
epublish
Résumé
Psoriasis is a common immune-mediated, chronic, inflammatory skin disease that affects approximately 2-3% of the population worldwide. Although there is increasing evidence regarding the essential roles of the interleukin (IL)-23/IL-17 axis and dendritic cell (DC)-T cell crosstalk in the development of skin inflammation, the contributions of mitochondrial function to psoriasis are unclear. In a mouse model of imiquimod (IMQ)-induced psoriasiform skin inflammation, we found that hematopoietic cell-specific genetic deletion of p32/C1qbp, a regulator of mitochondrial protein synthesis and metabolism, protects mice from IMQ-induced psoriatic inflammation. Additionally, we demonstrate that p32/C1qbp is an important regulator of IMQ-induced DC activation, both
Identifiants
pubmed: 34421919
doi: 10.3389/fimmu.2021.714897
pmc: PMC8378889
doi:
Substances chimiques
Biomarkers
0
Cytokines
0
Inflammation Mediators
0
Reactive Oxygen Species
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
714897Informations de copyright
Copyright © 2021 Mizuguchi, Gotoh, Nakashima, Setoyama, Takata, Ohga and Kang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Prog Neuropsychopharmacol Biol Psychiatry. 2018 Apr 20;83:8-17
pubmed: 29287831
Int Immunopharmacol. 2020 Mar;80:106215
pubmed: 31982823
Br J Dermatol. 2013 Jun;168(6):1303-10
pubmed: 23374051
Biochimie. 2020 Dec;179:146-156
pubmed: 33007409
Med Microbiol Immunol. 2019 Oct;208(5):631-640
pubmed: 30306260
J Dermatol. 2020 Feb;47(2):104-113
pubmed: 31833093
Nat Rev Immunol. 2009 Oct;9(10):679-91
pubmed: 19763149
Exp Dermatol. 2016 Jun;25(6):453-9
pubmed: 26841714
Int Arch Allergy Immunol. 2015;166(2):135-49
pubmed: 25824670
J Drugs Dermatol. 2015 Oct;14(10):1093-6
pubmed: 26461819
Br J Dermatol. 2017 Jan;176(1):212-215
pubmed: 27105586
Free Radic Biol Med. 2009 Oct 1;47(7):891-905
pubmed: 19577640
J Exp Med. 2010 Apr 12;207(4):721-30
pubmed: 20231379
Cell Metab. 2019 May 7;29(5):1104-1118.e6
pubmed: 30773462
J Dermatol. 2018 Mar;45(3):279-286
pubmed: 29226369
N Engl J Med. 2009 Jul 30;361(5):496-509
pubmed: 19641206
Immunol Rev. 2007 Oct;219:118-42
pubmed: 17850486
Immunity. 2011 Oct 28;35(4):596-610
pubmed: 21982596
Immunity. 2019 Oct 15;51(4):671-681.e5
pubmed: 31451397
Immunity. 2016 Oct 18;45(4):761-773
pubmed: 27692612
Nat Commun. 2017 Feb 01;8:14275
pubmed: 28145433
J Biol Chem. 1997 Sep 26;272(39):24363-70
pubmed: 9305894
Biosci Rep. 2020 Nov 27;40(11):
pubmed: 33165592
Nat Rev Rheumatol. 2019 Nov;15(11):645-656
pubmed: 31485004
Sci Rep. 2021 Apr 22;11(1):8775
pubmed: 33888854
Immunity. 2009 Aug 21;31(2):331-41
pubmed: 19682929
Nat Rev Immunol. 2019 Aug;19(8):490-502
pubmed: 30992525
J Invest Dermatol. 2019 Jan;139(1):146-156
pubmed: 30120937
Cell. 1991 Jul 26;66(2):383-94
pubmed: 1830244
Am J Hum Genet. 2017 Oct 5;101(4):525-538
pubmed: 28942965
Eur J Pharmacol. 2020 Jun 15;877:173088
pubmed: 32234429
iScience. 2020 Oct 07;23(11):101654
pubmed: 33103089
J Invest Dermatol. 2013 Feb;133(2):377-85
pubmed: 23014338
Annu Rev Pathol. 2012;7:385-422
pubmed: 22054142
Exp Dermatol. 2014 Sep;23(9):607-14
pubmed: 24980550
Clin Exp Dermatol. 2001 Jun;26(4):314-20
pubmed: 11422182
J Invest Dermatol. 2009 Jan;129(1):79-88
pubmed: 18633443
Nature. 2007 Feb 22;445(7130):866-73
pubmed: 17314973
Immunity. 2011 May 27;34(5):637-50
pubmed: 21616434
BMJ Open. 2019 Mar 20;9(3):e028116
pubmed: 30898836
J Clin Med. 2019 Apr 15;8(4):
pubmed: 30991713
Biochimie. 2019 Mar;158:102-110
pubmed: 30599182
J Exp Med. 2009 Aug 31;206(9):1983-94
pubmed: 19703986
STAR Protoc. 2021 Mar 26;2(2):100401
pubmed: 33851138
PLoS One. 2014 Mar 07;9(3):e91146
pubmed: 24608112
Annu Rev Immunol. 2014;32:227-55
pubmed: 24655295
Arch Dermatol. 2004 Dec;140(12):1490-5
pubmed: 15611427
Rheumatology (Oxford). 2004 Jan;43(1):22-6
pubmed: 12890860
J Allergy Clin Immunol. 2011 Mar;127(3):787-94.e1-9
pubmed: 21377044
EBioMedicine. 2017 Jun;20:161-172
pubmed: 28549777
Am J Med. 1997 May 5;102(5A):9-15
pubmed: 9217657
Nat Immunol. 2002 Feb;3(2):196-200
pubmed: 11812998
Redox Biol. 2015 Dec;6:472-485
pubmed: 26432659
Cardiovasc Res. 2017 Aug 1;113(10):1173-1185
pubmed: 28498888
Mol Cell Biol. 2010 Mar;30(6):1303-18
pubmed: 20100866
Br J Dermatol. 2011 Mar;164(3):670-2
pubmed: 21062268
Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3572-7
pubmed: 10097078
Blood. 2008 Mar 15;111(6):2973-6
pubmed: 18198348
Int J Mol Sci. 2020 Aug 27;21(17):
pubmed: 32867343
J Biol Chem. 2001 Feb 16;276(7):4588-96
pubmed: 11092892
Immunol Rev. 2008 Jun;223:271-83
pubmed: 18613842
Nucleic Acids Res. 2012 Oct;40(19):9717-37
pubmed: 22904065
Cell Rep. 2018 Nov 13;25(7):1800-1815.e4
pubmed: 30428349
Br J Dermatol. 2015 Jul;173(1):239-41
pubmed: 25495649
Cell. 2019 May 16;177(5):1201-1216.e19
pubmed: 31031005
Nat Rev Dis Primers. 2016 Nov 24;2:16082
pubmed: 27883001
Proc Natl Acad Sci U S A. 2014 Aug 19;111(33):E3422-31
pubmed: 25092341
Nature. 2010 Oct 21;467(7318):967-71
pubmed: 20962846
Sci Signal. 2013 Feb 05;6(261):ra8
pubmed: 23386745
J Immunol. 2009 May 1;182(9):5836-45
pubmed: 19380832
J Dermatolog Treat. 2015 Feb;26(1):32-6
pubmed: 24552447